Shkreli ordered to return $64M, is barred from drug industry
A federal judge has ordered Martin Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life.
'Pharma Bro' Shkreli loses 2nd bid for early prison release
FILE - In this Aug. 3, 2017, file photo, Martin Shkreli arrives at federal court in New York. Matsumoto noted that Shkreli recently had a two-hour Zoom session with his lawyers, as well as several phone calls up to an hour in length. Prosecutors said that, as of Jan. 6, there were no positive cases in Shkreli’s housing unit. Shkreli, who was ordered to forfeit $7.3 million as part of his sentence, is due to be released from prison in September 2023. He is also known for attacking critics on social media and offering a bounty to anyone who could give him one of Hillary Clinton’s hairs.
'Delusional' Martin Shkreli denied prison release by judge
NEW YORK A judge rejected the request of convicted pharmaceutical executive Martin Shkreli to be let out of prison to research a coronavirus treatment, noting that probation officials viewed that claim as the type of delusional self-aggrandizing behavior that led to his conviction. U.S. District Judge Kiyo Matsumoto said in a nine-page ruling Saturday that the man known as the Pharma Bro" failed to demonstrate extraordinary and compelling factors that would require his release under home confinement rules designed to move vulnerable inmates out of institutions during the pandemic. Disappointed but not unexpected, Shkrelis lawyer, Benjamin Brafman, said. A judge ordered Shkreli to forfeit $7.3 million. He is also known for attacking critics on social media and offering a bounty to anyone who could give him one of Hillary Clintons hairs.